歡迎光臨源葉生物,登錄 | 注冊 |
當(dāng)前位置: 首頁 > 小分子抑制劑 > Angiogenesis > LFM-A13

瀏覽歷史

S81443

LFM-A13

源葉(MedMol) 99%
  • 英文名:
  • LFM-A13
  • 別名:
  • trans-4,5-didehydro-neral; 2,4,6-Octatrienal,3,7-dimethyl; trans-dehydroneral; dehydrocitral; a-Cyano-b-hydroxy-b-methyl-N-(2,5-dibromophenyl)propenamide;
  • CAS號:
  • 244240-24-2
  • 分子式:
  • Br2C11H8N2O2
  • 分子量:
  • 360
  • 核磁/質(zhì)譜:
品牌貨號產(chǎn)品規(guī)格價(jià)格(RMB) 庫存(上海) 北京 武漢 南京 數(shù)量計(jì)量單位 加入購物車...
源葉(MedMol) S81443-5mg 99% ¥400.00元 7 - - - EA 加入購物車
源葉(MedMol) S81443-10mg 99% ¥600.00元 6 - - - EA 加入購物車
源葉(MedMol) S81443-50mg 99% ¥2400.00元 3 - - - EA 加入購物車
大包裝詢價(jià)

提交您的電話號碼并同意《個(gè)人信息授權(quán)與保護(hù)申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻(xiàn)

質(zhì)檢證書(COA)

摩爾濃度計(jì)算器

相關(guān)產(chǎn)品

  • 提示:詳情請下載說明書。
  • 產(chǎn)品描述: LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.
  • 靶點(diǎn): Plx1:10 μM (IC50);PLK3:61 μM (IC50);BRK:267 μM (IC50);BMX:281 μM (IC50);FYN:240 μM (IC50);Hepatocyte growth factor receptor kinase (Met):215 μM (IC50);BTK:2.5 μM (IC50);PLK;?JAK;?BTK
  • 體內(nèi)研究:
    LFM-A13 (25, 50 and 100 mg/kg) shows no apparent toxicity to rats. LFM-A13 (50 mg/kg, three times a week, i.p.) attenuates DMBA-induced mammary tumorigenesis in mice. LFM-A13 alone or in combination with paclitaxel shows marked effect on the DMBA-induced breast tumor incidence, mean tumor numbers, average tumor weight, and size in BALB/c mice. LFM-A13 (50 mg/kg, three times a week, i.p.) significantly decreases PLK1, cyclin D1, CDK-4, P53 and Bcl-2 expression, but increases the expression of p21, IκB, Bax and caspase 3 expression in mice. LFM-A13 (200 mg/kg) does not cause hematologic toxicity in rats. LFM-A13 (10 or 50 mg/kg, i.p.) exhibits anti-tumor effects dose dependently in the MMTV/Neu transgenic mouse model of breast cancer
  • 參考文獻(xiàn):
    1. Mahajan S, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem. 1999 Apr 2;274(14):9587-99. 2. van den Akker E, et al. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity. Biol Chem. 2004 May;385(5):409-13. 3. Sahin K, et al. LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice. Invest New Drugs. 2017 Nov 15. 4. Uckun FM, et al. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg Med Chem. 2007 Jan 15;15(2):800-14. Epub 2006 Oct 26.
  • 溶解性: DMSO  :  ≥  42  mg/mL  (116.67  mM)
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.778 ml 13.889 ml 27.778 ml
    5 mM 0.556 ml 2.778 ml 5.556 ml
    10 mM 0.278 ml 1.389 ml 2.778 ml
    50 mM 0.056 ml 0.278 ml 0.556 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號:

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:


質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學(xué)研究,銷售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷售條款。